Zealand Pharma A/S (ZEAL) and Xencor Inc. (NASDAQ:XNCR) Contrasting side by side

We are contrasting Zealand Pharma A/S (NASDAQ:ZEAL) and Xencor Inc. (NASDAQ:XNCR) on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zealand Pharma A/S N/A 0.00 N/A 3.00 5.18
Xencor Inc. 40.60M 43.12 70.41M -1.35 0.00

Table 1 highlights Zealand Pharma A/S and Xencor Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Zealand Pharma A/S 0.00% 0% 0%
Xencor Inc. -173.42% -13.3% -11.9%

Analyst Ratings

The Recommendations and Ratings for Zealand Pharma A/S and Xencor Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Zealand Pharma A/S 0 0 0 0.00
Xencor Inc. 1 0 6 2.86

Meanwhile, Xencor Inc.’s consensus price target is $41, while its potential upside is 31.83%.

Insider and Institutional Ownership

Zealand Pharma A/S and Xencor Inc. has shares owned by institutional investors as follows: 9.28% and 85.5%. Competitively, Xencor Inc. has 13.5% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zealand Pharma A/S 6.55% 7.93% 34.59% 9.24% -2.23% 33.89%
Xencor Inc. -3.26% -13.74% -24.23% -25.22% 6.9% -13.88%

For the past year Zealand Pharma A/S has 33.89% stronger performance while Xencor Inc. has -13.88% weaker performance.

Summary

On 7 of the 11 factors Zealand Pharma A/S beats Xencor Inc.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.